Nystatin

Manufacturer
XGen Pharmaceuticals DJB, Inc.
Effective date
2022-12-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
20
Source
legacy-cache
Hydrated at
2026-08-01 21:44:26

Label at a glance#

ProductNystatin
Active ingredientNYSTATIN
Label structure10 sections

Indications and uses

Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans  and other susceptible Candida species. Nystatin Topical Powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

Dosage and administration

Very moist lesions are best treated with the topical dusting powder. Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

Storage and handling

Store at 20º - 25ºC (68º - 77ºF) and excursions permitted to 15º - 30ºC (59º - 86ºF)  [See USP Controlled Room Temperature]. Avoid excessive heat (40ºC/104ºF). Keep tightly closed.  Keep out of reach of children. Manufactured for  X-Gen Pharmaceuticals, Inc. Big Flats, NY 14814 Revised January 2018 NYTP-PI-04

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. The molecular formula for nystatin is C 47H 75NO 17. The molecular weight of nystatin is 926.1.  

structural formula
structural formula

Nystatin Topical Powder is for dermatologic use.

Nystatin Topical Powder contains 100,000 USP nystatin units per gram dispersed in talc.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

 Nystatin is not absorbed from intact skin or mucous membrane.

Microbiology

MICROBIOLOGY SECTION

Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida  albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis  glabrata, Tricophyton  rubrum, T.  mentagrophytes.

Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the  subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida ( C.  tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become  cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.

Nystatin Topical Powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

 Nystatin Topical Powder is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Nystatin Topical Powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended  that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR THE PATIENT

INFORMATION FOR PATIENTS SECTION

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.

2.  Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt  or discontinue therapy until the prescribed course of treatment is completed.

3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests

LABORATORY TESTS SECTION

 If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

 No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

Pregnancy Teratogenic Effects Category C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

 It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

 Safety and effectiveness have been established in the pediatric population from birth to 16 years. ( See DOSAGE AND ADMINISTRATION ).

Geriatric Use

GERIATRIC USE SECTION

Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

 The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. ( See PRECAUTIONS, General )

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Very moist lesions are best treated with the topical dusting powder.

Adults and Pediatric Patients (Neonates and Older):

SPL UNCLASSIFIED SECTION

Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

HOW SUPPLIED

HOW SUPPLIED SECTION

 Nystatin Topical Powder is supplied as 100,000 units nystatin per gram in plastic squeeze bottles.

NDC 39822-3015-1 for 15 g.

NDC 39822-3015-3 for 30 g.

NDC 39822-3015-6 for 60 g.

STORAGE

STORAGE AND HANDLING SECTION

Store at 20º - 25ºC (68º - 77ºF) and excursions permitted to 15º - 30ºC (59º - 86ºF)  [See USP Controlled Room Temperature]. Avoid excessive heat (40ºC/104ºF). Keep tightly closed.  Keep out of reach of children.

Manufactured for 
X-Gen Pharmaceuticals, Inc.
Big Flats, NY 14814

Revised January 2018

NYTP-PI-04

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

15g Presentation

SPL UNCLASSIFIED SECTION

NDC 39822-3015-1
Nystatin Topical Powder, USP
100,000 USP units per gram
15 grams
FOR TOPICAL USE ONLY
Not for Ophthalmic Use
Rx Only 

 X-Gen Pharmaceuticals, Inc. 

Xg 15 g
Xg 15 g

30g Presentation

SPL UNCLASSIFIED SECTION

NDC 39822-3015-3
Nystatin Topical Powder, USP
100,000 USP units per gram
30 grams
FOR TOPICAL USE ONLY
Not for Ophthalmic Use
Rx Only
 X-Gen Pharmaceuticals, Inc.

xg30g
xg30g

60g Presentation

SPL UNCLASSIFIED SECTION

NDC 39822-3015-6
Nystatin Topical Powder, USP
100,000 USP units per gram
60 grams
FOR TOPICAL USE ONLY
Not for Ophthalmic Use
Rx Only
 X-Gen Pharmaceuticals, Inc.

xg 60 g
xg 60 g

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
39822-3015-1GM - Gram39822-3015027aace4-566e-4a88-82da-c81a9141ea8412014-10-03
39822-3015-3GM - Gram39822-3015792a1891-6096-4d1a-a49e-6824c207866a12014-10-03
39822-3015-6GM - Gram39822-30152698b1af-3b60-4503-8459-18c5afc04ef712014-10-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NYSTATINACTIVE INGREDIENTBDF1O1C72E7
NYSTATINACTIVE MOIETYBDF1O1C72E7
TALCINACTIVE INGREDIENT7SEV7J4R1U7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
39822-301539822-3015-1, 39822-3015-3, 39822-3015-6

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
TALC7SEV7J4R1UIACT
NYSTATINBDF1O1C72EACTIB

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 35 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
TALCTALC7SEV7J4R1UGUM, CHEWING / BUCCALNAExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, ORALLY DISINTEGRATING / ORAL80 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UPOWDER, FOR SUSPENSION / ORAL735 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, COATED / ORAL320.75 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UOINTMENT / TOPICAL74.6 %w/wExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UDROPS / ORALNAExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1USUSPENSION / ORAL234 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, FOR SUSPENSION / ORAL24 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, FILM COATED / ORAL91 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE, COATED / ORAL87 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1USUSPENSION, EXTENDED RELEASE / ORAL46 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / BUCCAL15 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UGRANULE / ORAL322 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, EXTENDED RELEASE / ORAL300 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UPOWDER / TOPICAL9235 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UPELLET / ORAL69 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, CHEWABLE, EXTENDED RELEASE / ORAL18 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, DELAYED RELEASE / ORAL349 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UGRANULE, DELAYED RELEASE / ORAL525 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, FILM COATED, EXTENDED RELEASE / ORAL60 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1ULOZENGE / ORAL50 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / ORAL1000 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, CHEWABLE / ORAL202 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / SUBLINGUAL32.4 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / RECTAL32.4 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE, COATED PELLETS / ORAL14 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE, DELAYED RELEASE / ORAL420 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE, EXTENDED RELEASE / ORAL5119 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE / ORAL729 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, DELAYED RELEASE PARTICLES / ORAL56 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL357 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UELIXIR / ORAL4.5 mg/5mlExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UGRANULE, FOR SUSPENSION / ORAL296 mgExact identifier — unii candidate
35 equally ranked IID candidates
TALCTALC7SEV7J4R1UCAPSULE, COATED, EXTENDED RELEASE / ORAL20 mgExact identifier — unii candidate
35 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A065175-001NYSTATINNYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-17

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-1784e616aacf4f…
2026-08-18 06:07:402026-07A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICAL2004-12-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-171e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-178072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-175c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-175d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-174b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-1774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-1787673890dc5c…
2021-03-12 10:30 UTC2021-03A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-175aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-178869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-173f01610625f2…
2019-09-15 20:21 UTC2019-09A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17b00525d2431f…
2019-07-19 19:46 UTC2019-07A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-176a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-171c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17053a50430f4f…
2023-01-26 05:58 UTC2023-01A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-173bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-173a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A065175-001NYSTATIN100,000 UNITS/GMPOWDER / TOPICALAT2004-12-17f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065175-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065175-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065175-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065175-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065175-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065175-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065175-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065175-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065175-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065175-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065175-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065175-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065175-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065175-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065175-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065175-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065175-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065175-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A065175-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065175-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065175-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065175-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A065175-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A065175-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065175-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065175-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065175-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065175-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065175-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065175-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065175-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A065175-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A065175-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A065175-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A065175-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A065175-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A065175-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1405f80e-106b-4724-e063-6294a90a3b9ba6f88015-4cac-4cb2-9012-92cc5390b5df2024-03-19Adverse reactionsExact identifier
spl set id: a6f88015-4cac-4cb2-9012-92cc5390b5df

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.